CPP-Exendin-4 Peptide Conjugates for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's face challenges due to the blood-brain barrier's limitation on drug delivery, particularly for macromolecules and small molecules, necessitating the development of novel formulations that can effectively deliver therapeutic agents without cytotoxicity.
Innovation Solution
A peptide represented by the amino acid sequences SEQ ID NO: 1 or 2, formed by conjugating exendin-4 with a cell-penetrating peptide (ACP2 or ACP4), enhances blood-brain barrier permeability, prolongs half-life, and suppresses inflammatory markers like IL-1β, IL-6, and TNFα while increasing Arg-1 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug delivery methods are used to treat neurodegenerative diseases, then therapeutic agents can be administered, but the blood-brain barrier severely limits the transport of substances including macromolecules and small molecules into brain tissue
Solution Approach 1:
The patent uses cell-penetrating peptides (CPPs) as intermediary carriers to facilitate the transport of therapeutic macromolecules across the blood-brain barrier. The CPPs form complexes with the therapeutic agents, enabling them to penetrate the BBB through transcytosis while maintaining the integrity of the barrier. This intermediary approach allows effective delivery of proteins and other large molecules that would otherwise be blocked by the BBB.
Solution Approach 2:
The patent creates composite formulations by conjugating cell-penetrating peptides with therapeutic macromolecules. These composite structures combine the BBB-penetrating capability of the CPPs with the therapeutic activity of the macromolecules, achieving both barrier penetration and therapeutic effectiveness simultaneously.
2Object-affected harmful factors
If cell-permeable peptides are used to improve blood-brain barrier permeability, then delivery of macromolecules is enhanced, but the peptide must be designed to achieve both permeability and therapeutic effect
Solution Approach 1:
The patent divides the peptide structure into distinct functional segments: a cell-penetrating peptide portion that facilitates BBB crossing and a therapeutic payload portion that provides the desired biological activity. This segmentation allows each portion to be optimized independently for its specific function while maintaining overall efficacy.
Solution Approach 2:
The cell-penetrating peptide component serves multiple functions: it acts as a BBB penetrant, a cellular transporter, and a protective carrier for the therapeutic macromolecule. This multi-functionality reduces the need for separate components and simplifies the overall delivery system.
3Reliability
If therapeutic agents are delivered to the brain, then treatment effects are achieved, but the half-life of the peptide in blood circulation is limited
Solution Approach 1:
The patent employs preliminary modification of the therapeutic agent by conjugating it with cell-penetrating peptides before administration. This preliminary complex formation protects the macromolecule from rapid degradation and clearance, extending its circulation half-life while maintaining the ability to penetrate the BBB and exert therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide achieves enhanced delivery and accumulation at inflamed brain regions, effectively suppressing inflammation and treating or preventing neurodegenerative diseases by improving BBB permeability and half-life, with ACP4-exendin-4 showing superior anti-inflammatory effects.
Implementation Method 1
cell-permeable peptides (CPPs) have attracted attention for their ability to improve the utilization of macromolecules-such as therapeutic proteins and genes-that have been difficult to use as drugs due to poor membrane permeability
Implementation Method 2
enhancing delivery and accumulation at the site of action, particularly inflammatory regions within the brain. It may also prolong the peptide's half-life in blood circulation
Implementation Method 3
the peptide or pharmaceutical composition of the present invention exhibits high permeability through the blood-brain barrier (BBB), thereby enhancing delivery and accumulation at the site of action, particularly inflammatory regions within the brain. It may also prolong the peptide's half-life in blood circulation and improve inflammatory conditions
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention relates to a novel brain disease therapeutic and a use thereof. A peptide or pharmaceutical composition according to the present invention can increase the level of delivery to a target site (in particular, inflamed areas of the brain) due to having a high blood-brain barrier penetration level, can have an increased half-life in the bloodstream, and can exhibit anti-inflammatory activity and treat or prevent brain diseases by reducing the level of inflammation.